News | June 07, 2022
MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
These and many other questions gather worldwide experts of the pharmaceutical industry at the PHARMAP 2022 which takes place in Berlin, Germany on June, 20 - 21, 2022
The site, located in Berkeley County, will be operated using the same quality standards as DuPont’s Healthcare Industries Materials Site, the company’s longstanding biopharmaceutical manufacturing site in Hemlock, Michigan
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Subscribe To Our Newsletter & Stay Updated
